BC Extra | May 16, 2019
Company News

Genentech adds to autoimmune pipeline with Parvus deal

In its second deal based on its immunomodulatory platform, Parvus granted Genentech rights to develop and commercialize its Navacim nanoparticle therapeutics to treat inflammatory bowel disease (IBD), autoimmune liver diseases and celiac disease. Parvus Therapeutics...
BioCentury | Jul 13, 2018
Strategy

Roche’s partnering priority

As James Sabry gets set to lead partnering for all of Roche pharma, his first order of business might be to build out the company’s late-stage pipeline ahead of an impending patent cliff that puts...
BC Extra | Nov 6, 2017
Preclinical News

Team identifies new target for MM CAR T therapy

In a paper published in Nature Medicine , researchers at Osaka University and colleagues identified activated integrin beta(7) as a new target for a chimeric antigen receptor (CAR) T cell therapy for multiple myeloma, demonstrating that...
BC Week In Review | May 27, 2013
Clinical News

Etrolizumab: Additional Phase II data

Additional data from the Phase II EUCALYPTUS trial in 124 patients with moderate-to-severely active UC showed that 20.5% of patients receiving once-monthly 100 mg subcutaneous etrolizumab plus immunosuppressant therapy and 10.3% of patients receiving once-monthly...
BC Week In Review | Feb 4, 2013
Clinical News

Etrolizumab: Phase II data

Roche disclosed in its 2012 earnings that the Phase II EUCALYPTUS trial in 120 patients with UC showed that etrolizumab plus immunosuppressant therapy met the primary endpoint of clinical remission as measured by Mayo Clinic...
BioCentury | Jul 16, 2012
Strategy

Burying Nutley

When Roche acquired Genentech Inc. in 2009, it was clear the pharma's Nutley, N.J., facility had been underperforming for years. Three years later, the continued poor performance of the Nutley site made it an obvious...
Items per page:
1 - 6 of 6